Moxifloxacin-associated Neutropenia in a Patient Planned for Renal Transplantation
Incidence of tuberculosis (TB) in patients on maintenance hemodialysis (MHD) and in renal transplant (RT) recipients is 10-15%. Rifampicin-based antitubercular therapy is the standard of care for the management of TB across the world. However, rifampicin is generally avoided in transplant recipients because of significant interaction with calcineurin inhibitors, thereby increasing the cost of therapy, sub therapeutic drug levels, and risk of rejection. In MHD patients, rifampicin is associated with accelerated hypertension due to drug interaction through cytochrome P450 enzymes, and therefore, is often avoided in certain situation. [1] Therefore, in these situations, fluoroquinolone is mostly used in place of rifampicin. Moxifloxacin is a common broad-spectrum fluoroquinolone used for the management of respiratory infections and is generally considered safe and well-tolerated. In view of good efficacy against Mycobacterium, moxifloxacin is used in these patients as part of antituberculosis therapy. The adverse effects reported, in general, are predominantly gastrointestinal or central nervous system effects with reports of QTc prolongation, phototoxicity, and tendinopathy. There are no characteristic hematological adverse events described. Here, we report a patient on MHD who developed neutropenia following moxifloxacin-based antituberculosis therapy (ATT).
A 30-year-old male patient with end-stage renal disease (ESRD) on MHD for 1 year was initiated on an intensive phase of ATT with isoniazid, rifampicin, pyrazinamide, and ethambutol for disseminated TB. The patient responded clinically, and following completion of intensive phase of therapy, he was shifted to a maintenance phase with isoniazid and moxifloxacin, as he was planned for live-related RT in few days. Routine blood investigation done after 5 days of changing ATT, revealed significant leucopenia (2 × 10 9 /L) with neutropenia (0.8 × 10 9 /L). He was otherwise asymptomatic and was not on any other medication, which could explain his cytopenia. Peripheral smear examination was normal, and bone marrow examination was also normal. As the only change in medication was the introduction of moxifloxacin and there were sporadic reports of moxifloxacin-induced neutropenia, moxifloxacin was stopped. He was placed on neutropenic precautions, and his leukopenia resolved over the next 4 days. Patient was then started on levofloxacin, which he tolerated well; he underwent RT after 2 weeks. He did not have recurrence of cytopenia and completed 1-year ATT therapy following RT.
Our patient had findings consistent with moxifloxacin-induced neutropenia. All the three cases which have been reported earlier also had similar presentation [2] [3] [4] [ Table 1 ]. Though reports of ciprofloxacin and norfloxacin-induced neutropenia are available, we could not find any report of cytopenia following levofloxacin administration. We also performed a bone marrow evaluation in our patient to rule out any other cause, which was not done in the earlier reports. The rapid onset as well as recovery of neutropenia after stoppage of moxifloxacin suggests the possibility of hypersensitivity reactions. [5] However, the absence of skin eruptions and systemic symptoms makes type-1 hypersensitivity reactions unlikely. Whether a prior drug exposure results in an antibody-mediated reaction needs to be studied further. [5, 6] Recovery from cytopenia is complete and starts as soon as the offending drug is stopped. The drugs commonly responsible for cytopenia are penicillin, β-lactam antibiotics, carbamazepine, valproate, clozapine, and propylthiouracil. Nevertheless, fluoroquinolone-induced neutropenia is also reported, though uncommonly.
Moxifloxacin-induced neutropenia is an unusual yet potentially serious adverse effect. It has to be considered in all patients with cytopenia in whom moxifloxacin was recently introduced and may be of significance in RT recipients who have multiple other etiologic factors for cytopenia, and are more likely to receive moxifloxacin as a part of the ATT regimen. Early discontinuation of the drug results in prompt resolution of neutropenia.
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There are no conflicts of interest. [2] 77/F Cellulitis Cirrhosis Day 5 2 days Berk et al. [3] 32/F Lobar pneumonia Breast carcinoma Day 2 4 days Chen et al. [4] 76/M CAP None Day 3 2 days CAP: Community acquired pneumonia, F: Female, M: Male Sir, We report the genetic screening results in two siblings with steroid-resistant nephrotic syndrome (SRNS) performed at different time points in the clinical course, which provided a unique opportunity to highlight the utility of genetic diagnosis at the right time. A subset of children with SRNS has an underlying mutation in the podocyte-specific genes. Recent studies analyzing genetic mutations in children with SRNS found 10-32% of the SRNS cohort, harboring a disease-causing variant with a higher proportion in familial cases (67%) as compared with sporadic cases (25%). [1, 2] Genetic testing in these patients will not only aid in diagnosis and prognostication of the disease but also help in limiting the exposure to expensive immunosuppression therapies and related complications.
We herein present a consanguineous Indian family with two affected children suffering from SRNS. The elder sibling (P1) presented with SRNS at 3 years of age and was diagnosed to have FSGS (not otherwise specified) on renal biopsy. She initially received empirical immunosuppression therapy with steroids, cyclosporine, mycophenolate mofetil, and antiproteinuric drugs over 30 months with no response in proteinuria. She also required multiple hospitalizations for infections and for hypertensive encephalopathy with seizures because of posterior reversible encephalopathy syndrome. She progressed to end stage renal disease (ESRD) by 6 years of age requiring dialysis for 12 months along with a unilateral nephrectomy for uncontrolled hypertension and proteinuria. The child succumbed to severe sepsis at the age of 7 years. The genetic screening for NPHS2 and WT1 using Sanger sequencing was performed when the child was in ESRD. A homozygous pathogenic variant c.211C>T; p.R71X in exon 1 of the NPHS2 gene was identified. Within a year, the younger sibling was born and was kept under close monitoring for proteinuria. Younger sibling (P2) was diagnosed as a case of nephrotic syndrome at the age of 3.5 years on routine urine screening, although she had no edema and renal biopsy-revealed FSGS. Sanger sequencing revealed the same homozygous pathogenic variant c.211C>T; p.R71X in exon 1 of the NPHS2 gene, which was identified in the older sibling. In view of genetic diagnosis and family history, we presumed a poor response to steroid therapy and hence initiated on tacrolimus as a first-line therapy. She received tacrolimus for 18 months without reduction in proteinuria. In view of the genetic diagnosis, prolonged course of tacrolimus was not considered. The child progressed to CKD stage 3 by 7 years of age. The child did not have any hospitalization for infections or medication-related adverse effects. Parents of the siblings were identified to be heterozygous carriers for c.211C>T; p.R71X variant, compatible with recessive inheritance [ Figure 1 ]. In addition, the mother who was the potential donor did not harbor the R229Q variant, which increases the risk of proteinuria in adulthood.
The timing of genetic screening in the siblings reveals the utility of genetic screening. Besides assisting in molecular diagnosis, genetic testing also helped in deciding the treatment and in prognostication. Genetic diagnosis in the elder sibling helped us plan timely screening for proteinuria in the younger child. The genetic testing at the time of diagnosis helped to individualize immunosuppressive treatment. With the identification of the pathogenic variant in the sibling 2 at time of diagnosis of nephrotic syndrome steroid was not used for the treatment; instead, tacrolimus was given as the first-line treatment, thus avoiding the side effects of steroids. Tacrolimus was considered in this child as there were reports of partial response to calcineurin inhibitors in those with a genetic cause of SRNS. [3] The genetic information helped in predicting the response to tacrolimus and counseling the parents at the time of initiation of treatment about the efficacy of treatment. As expected, there was no significant response to tacrolimus. Further immunosuppression was avoided, which helped in reducing the morbidity because of serious
